Agilent remains focused

Agilent’s spectrum of innovative product line in Indian chromatography market has kept its space intact


Rank: 3
Organization: Agilent Technologies
President and Country GM: Mr Parmeet S Ahuja
Bioscience revenue: Rs 463 crore


In FY 2014-15, Agilent India's life sciences business is estimated at Rs 463 crore with a growth of over 10 percent as compared to FY2013-14 when it recorded Rs 423 crore (15 percent growth). Slowdown can be been broadly attributed to the overall market scenario and lack of funds in government and research institutes.

Despite the prevailing conditions due to which customers across markets have been very cautious in purchase, Agilent has been able to retain its growth to some extent. One of the biggest contributor to the Agilent's Life Sciences and Chemical Analysis (LSCA) business in India has been the pharma sector. It has been also growing significantly in food testing where it has done exceedingly well in last few years.

The other areas that it has been focusing on are material and environmental sciences. In parallel, it has also been reaching out to colleges and universities and the focus is on the direct channels so that there is quality. The company delivers 100-150 platforms every year. Its percentage of contribution to new clients has been growing.

Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

National Health Policy

Is National Health Policy 2017 helpful for patients?

Send this article by email